Results for tag: "Transdermal Scopolamine"

Transdermal scopolamine, also known as hyoscine, is a therapeutic drug applied to the skin to prevent nausea and vomiting associated with motion sickness and postoperative recovery, as well as for other conditions under the guidance of a healthcare provider. It is a belladonna alkaloid and acts as an anticholinergic, impeding the action of the neurotransmitter acetylcholine within the central nervous system (CNS). This pharmaceutical market segment is a subset of the broader CNS drug category, which includes a range of medications aimed at treating neurological disorders, pain, psychological conditions, and an array of other health challenges that originate or manifest within the brain and spinal cord. Transdermal scopolamine offers the advantage of a steady release and systemic absorption, which can be beneficial for patients who have difficulty swallowing or maintaining oral medications due to vomiting. Leading companies that operate in the transdermal scopolamine market are Novartis AG, which markets the product under the brand name Transderm Scop; Baxter International Inc.; GlaxoSmithKline plc; Perrigo Company plc; Mylan N.V.; and Teva Pharmaceutical Industries Ltd. These companies are involved in the manufacture, distribution, and ongoing development of scopolamine-based therapies, ensuring a competitive landscape driven by product innovation, availability, and clinical effectiveness. Show Less Read more